[en] HIV-1 latency represents a major hurdle to the complete eradication of the virus from patients under highly active anti-retroviral therapy (HAART) regimens. One solution to this problem would be to eliminate the latently infected cellular reservoirs by forcing gene expression in presence of HAART to prevent spreading of the infection by the newly synthesized viruses. Many studies have reported that a combination of a histone deacetylase inhibitor (HDACi) (i.e. TSA, NaBut, Valproic acid,...) with a pro-inflammatory cytokine (i.e. TNF alpha, IL-1,...) reactivates in a synergistic manner HIV-1 transcription in latently infected cells. The aim of the present study was to determine whether HIV-1 protease inhibitors (PIs) used in HAART (such as Saquinavir, Indinavir, Nelfinavir, Lopinavir, Ritonavir and Amprenavir) could interfere with the potential purge of the cellular reservoirs induced by a combined treatment involving TSA and TNF alpha. We showed, in two HIV-1 latently infected cell lines (ACH-2 and U1) that all PIs efficiently inhibited release of mature viral particles but did neither affect cell apoptosis nor NF-kappa B induction and HIV-1 transcription activation following combined treatment with TNF alpha + TSA. This study is encouraging in the fight against HIV-1 and shows that PIs should be compatible with an inductive adjuvent therapy for latent reservoir reduction/elimination in association with efficient HAART regimens. (c) 2007 Elsevier Inc. All rights reserved.
Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53 (2002) 557-593
Pierson T., McArthur J., and Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18 (2000) 665-708
Persaud D., Zhou Y., Siliciano J.M., and Siliciano R.F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 77 (2003) 1659-1665
Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997) 1295-1300
Pomerantz R.J. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis 34 (2002) 91-97
Collman R.G., Perno C.F., Crowe S.M., Stevenson M., and Montaner L.J. HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol 74 (2003) 631-634
Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 (1999) 512-517
Chun T.W., Engel D., Mizell S.B., Ehler L.A., and Fauci A.S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188 (1998) 83-91
Duh E.J., Maury W.J., Folks T.M., Fauci A.S., and Rabson A.B. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 86 (1989) 5974-5978
Folks T.M., Clouse K.A., Justement J., Rabson A., Duh E., Kehrl J.H., et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 86 (1989) 2365-2368
Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
Van Lint C. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15 (1996) 1112-1120
Verdin E., Paras Jr. P., and Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12 (1993) 3249-3259
El Kharroubi A., Piras G., Zensen R., and Martin M.A. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 18 (1998) 2535-2544
Berger S.L. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12 (2002) 142-148
Eberharter A., and Becker P.B. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3 (2002) 224-229
Demonte D., Quivy V., Colette Y., and Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 68 (2004) 1231-1238
Quivy V., Adam E., Collette Y., Demonte D., Chariot A., Vanhulle C., et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 76 (2002) 11091-11103
Adam E., Quivy V., Bex F., Chariot A., Collette Y., Vanhulle C., et al. Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol Cell Biol 23 (2003) 6200-6209
Navikas V., Link J., Persson C., Olsson T., Hojeberg B., Ljungdahl A., et al. Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 9 (1995) 484-489
Pajonk F., Himmelsbach J., Riess K., Sommer A., and McBride W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62 (2002) 5230-5235
Lebbe C., Blum L., Pellet C., Blanchard G., Verola O., Morel P., et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. Aids 12 (1998) F45-F49
Schmidtke G., Holzhutter H.G., Bogyo M., Kairies N., Groll M., de Giuli R., et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 274 (1999) 35734-35740
Estaquier J., Lelievre J.D., Petit F., Brunner T., Moutouh-De Parseval L., Richman D.D., et al. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. J Virol 76 (2002) 5966-5973
Wolf T., Findhammer S., Nolte B., Helm E.B., and Brodt H.R. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors. Eur J Med Res 8 (2003) 17-24
Badley A.D., Roumier T., Lum J.J., and Kroemer G. Mitochondrion-mediated apoptosis in HIV-1 infection. Trends Pharmacol Sci 24 (2003) 298-305
Phenix B.N., Angel J.B., Mandy F., Kravcik S., Parato K., Chambers K.A., et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 16 (2000) 559-567
Badley A.D., Parato K., Cameron D.W., Kravcik S., Phenix B.N., Ashby D., et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 6 (1999) 420-432
Aries S.P., Weyrich K., Schaaf B., Hansen F., Dennin R.H., Dalhoff K., et al. T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1. Scand J Immunol 48 (1998) 86-91
Rouet F., Ekouevi D.K., Chaix M.L., Burgard M., Inwoley A., Tony T.D., et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43 (2005) 2709-2717
Folks T.M., Justement J., Kinter A., Dinarello C.A., and Fauci A.S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238 (1987) 800-802
Clouse K.A., Powell D., Washington I., Poli G., Strebel K., Farrar W., et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142 (1989) 431-438
De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 30 (2004) 115-133
Roberts N.A., Craig J.C., and Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. Aids 12 (1998) 453-460
Boffito M., Back D.J., Blaschke T.F., Rowland M., Bertz R.J., Gerber J.G., et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 19 (2003) 825-835
Berridge M.V. The Biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 4 (1996) 15-19
Yasuda J., Miyao T., Kamata M., Aida Y., and Iwakura Y. T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene. Virology 285 (2001) 181-192
Ghibelli L., Mengoni F., Lichtner M., Coppola S., De Nicola M., Bergamaschi A., et al. Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem Pharmacol 66 (2003) 1505-1512
Sloand E.M., Kumar P.N., Kim S., Chaudhuri A., Weichold F.F., and Young N.S. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94 (1999) 1021-1027
Phenix B.N., Lum J.J., Nie Z., Sanchez-Dardon J., and Badley A.D. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98 (2001) 1078-1085
Johnson N., Ng T.T., and Parkin J.M. Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis. Leuk Res 21 (1997) 961-972
Calza L., Manfredi R., and Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53 (2004) 10-14
Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids 12 (1998) F51-F58
Tran H., Robinson S., Mikhailenko I., and Strickland D.K. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res 44 (2003) 1859-1869
Moon H.S., and Yang J.S. Role of HIV Vpr as a regulator of apoptosis and an effector on bystander cells. Mol Cells 21 (2006) 7-20
Pinti M., Biswas P., Troiano L., Nasi M., Ferraresi R., Mussini C., et al. Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1. Exp Biol Med (Maywood) 228 (2003) 1346-1354
Olivetta E., and Federico M. HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis. Exp Cell Res 312 (2006) 890-900
Ventoso I., Navarro J., Munoz M.A., and Carrasco L. Involvement of HIV-1 protease in virus-induced cell killing. Antiviral Res 66 (2005) 47-55
Darnell G.A., Schroder W.A., Gardner J., Harrich D., Yu H., Medcalf R.L., et al. SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication. J Biol Chem 281 (2006) 31348-31358
Darnell G.A., Antalis T.M., Johnstone R.W., Stringer B.W., Ogbourne S.M., Harrich D., et al. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 23 (2003) 6520-6532
von Willebrand M., Zacksenhaus E., Cheng E., Glazer P., and Halaban R. The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 63 (2003) 1420-1429
Jang J.S., Lee S.J., Choi Y.H., Nguyen P.M., Lee J., Hwang S.G., et al. Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease. Oncogene 18 (1999) 1789-1796
Chau B.N., Borges H.L., Chen T.T., Masselli A., Hunton I.C., and Wang J.Y. Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat Cell Biol 4 (2002) 757-765
